FRAX597, a PAK1 inhibitor, synergises with gemcitabine in the reduction of pancreatic cancer growth

The effect of FRAX597, either alone or in combination with gemcitabine, on the human pancreatic cancer cell lines, PANC-1, MiaPaCa-2, and BxPC-3, and on the murine pancreatic cancer cell lines, Pan02 and LM-P, was examined in vitro.

Saved in:
Bibliographic Details
Published inPancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] Vol. 15; no. 3; p. S36
Main Authors Yeo, Dannel, He, Hong, Baldwin, Graham, Nikfarjam, Mehrdad
Format Journal Article
LanguageEnglish
Published Philadelphia Elsevier B.V 01.06.2015
Elsevier Limited
Subjects
Endocrinology & Metabolism
Gastroenterology and Hepatology
Pancreatic cancer
Online AccessGet full text

Cover

More Information
Summary:The effect of FRAX597, either alone or in combination with gemcitabine, on the human pancreatic cancer cell lines, PANC-1, MiaPaCa-2, and BxPC-3, and on the murine pancreatic cancer cell lines, Pan02 and LM-P, was examined in vitro.
ISSN:1424-3903
1424-3911
DOI:10.1016/j.pan.2015.05.155